Oxiracetam
Oxiracetam is a synthetic pyrrolidinone ("racetam") nootropic, structurally a cyclic GABA derivative, marketed in parts of Europe and Asia for age-related cognitive decline and vascular/degenerative dementia and used off-label by healthy adults as a cognitive enhancer. There is no adequate human evidence that oxiracetam improves cognition in healthy, cognitively normal people; the only supportive human data in that population is a single 12-subject acute study using a scopolamine amnesia model, and the disease trials (dementia, post-stroke) are small, old, industry-era, and give mixed-to-negative results including a clearly negative Alzheimer's trial. It is not approved by the US FDA or EMA and is sold as an unregulated "research chemical"/supplement, meaning product identity, purity, and dose are not quality-controlled. In controlled trials it was generally well tolerated at 1600 mg/day for up to a year with no severe adverse events and no routine-lab changes, but long-term safety, cardiovascular safety, and safety of the high or stacked doses used by enhancement users are essentially unstudied. It is renally cleared, so it accumulates in the elderly and anyone with reduced kidney function. In short, the efficacy evidence for the enhancement use case is weak to absent, the safety record is reassuring but shallow and short-term, and there is no data on the doses/populations that recreational users actually represent.
Mechanism of action
Pharmacokinetics
Roughly 3-8 hours in healthy younger adults (mean terminal half-life ~7.7 h in one comparison; ~6.1-6.6 h for the (S)-enantiomer in a phase I study). Prolonged in the elderly to ~12 h due to reduced renal clearance. Half-life is shortened by enzyme-inducing anticonvulsants (carbamazepine, valproate), which may require more frequent dosing in that population.
Short; peak serum levels at ~1-2 h after oral dosing (0.75-1.0 h for (S)-oxiracetam), with typical twice-daily dosing in trials. CNS exposure may outlast serum exposure.
Oral (tablet/capsule/solution) in clinical use; intravenous formulation used in some pharmacokinetic and hospital settings. Absolute oral bioavailability ~75%.
Minimal metabolism; eliminated predominantly as unchanged drug by the kidney (>90% of an IV dose recovered unchanged in urine within 48 h; ~84% of an oral dose in the elderly; ~55% urine + ~36% feces unchanged for the (S)-enantiomer). Clearance is renal-function-dependent, so it accumulates in the elderly and in renal impairment. This washout/accumulation information is for clinical monitoring only, not for evading any test.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- In elderly patients with mild-to-moderate degenerative or multi-infarct dementia, several small double-blind RCTs at 1600 mg/day reported statistically significant improvements versus placebo on measures of attention, memory, word fluency, reaction time, and some activities-of-daily-living scales.
- Results are inconsistent: a well-designed double-blind trial in probable Alzheimer's disease found no cognitive benefit, and other trials showed only selective or partial improvements.
- In 12 healthy volunteers, an acute oral dose (significant at 1600 mg) reduced scopolamine-induced memory/attention impairment - the only controlled signal in non-demented people, and it does not establish benefit in healthy users taking it for enhancement.
- In post-stroke vascular cognitive impairment, a meta-analysis of dementia treatments grouped oxiracetam among symptomatic agents with a modest pooled benefit, and a small combination trial with nicergoline reported improved MoCA scores; a large phase IV RCT described the effect as at most modest and was still maturing.
- No demonstrated benefit for cognition in healthy, cognitively normal adults - the population most likely to self-administer it.
Adverse effects by system
No cardiovascular adverse signal was reported in the available controlled trials, but cardiovascular safety was not a formal endpoint and there are no dedicated cardiac safety, ECG/QT, or blood-pressure studies - so cardiovascular safety at enhancement doses is effectively unknown.
No hepatotoxicity signal: routine blood chemistry (including liver-related labs) was unchanged over treatment up to one year in placebo-controlled dementia trials, and the drug undergoes minimal hepatic metabolism. Dedicated hepatic-safety and long-term data are limited.
No known endocrine or hypothalamic-pituitary-gonadal (HPTA) activity; oxiracetam is not androgenic and is not a SERM, and no hormonal effects were reported in trials. No dedicated endocrine studies exist, so absence of a signal is not proof of absence.
No human reproductive, fertility, or pregnancy safety data are available; use in pregnancy/lactation is unstudied and should be avoided.
Generally well tolerated in trials; phase I adverse events were mild-to-moderate and dose-independent. Class-typical CNS stimulation effects (insomnia, agitation, headache, anxiety, irritability) are commonly described for racetams but were not well quantified in oxiracetam trials; one geriatric trial recorded improvement in anxiety and emotional lability instead. Treat stimulation-type effects as plausible but not well characterized.
Not reported to be nephrotoxic, but the drug is almost entirely cleared unchanged by the kidney, so impaired renal function causes accumulation (demonstrated by ~50% longer half-life in the elderly). This is a clearance/accumulation concern rather than direct kidney toxicity.
No hematologic adverse signal: hematology labs were unchanged in controlled dementia trials. No dedicated hematologic-safety data beyond routine trial monitoring.
No dermatologic adverse effects were reported in the available human literature; no adequate data.
HPTA suppression & recovery
Suppression: None known - oxiracetam has no androgenic, anabolic, or SERM activity and no evidence of HPTA (hypothalamic-pituitary-gonadal axis) suppression.
HPTA suppression and post-cycle recovery are not relevant to this nootropic, and single-SERM or any SERM-based recovery protocols are not indicated for oxiracetam. If you are combining it with hormonally active compounds and have concerns about testosterone or fertility, do not self-manage recovery - obtain a full endocrine workup and defer to a qualified endocrinologist.
Monitoring
Cadence: Establish a baseline before use, recheck renal and general labs within the first 1-3 months of regular use, then at least annually or sooner if symptoms develop; more frequent renal monitoring in older users or anyone with kidney disease.
- New or worsening headache, marked insomnia, agitation, anxiety, or irritability
- Any allergic/hypersensitivity reaction (rash, swelling, difficulty breathing) - stop immediately and seek care
- New neurological symptoms or seizures, especially in anyone with epilepsy
- Signs of reduced kidney function (decreased urination, swelling, fatigue)
- Palpitations, chest pain, or fainting - seek medical evaluation
Contraindications
- Known hypersensitivity to oxiracetam or other racetams.
- Significant renal impairment - the drug is renally cleared and will accumulate; dosing must involve a clinician and dose reduction.
- Pregnancy and breastfeeding - no human safety data.
- Epilepsy or use of enzyme-inducing anticonvulsants (carbamazepine, valproate) without medical supervision - a pharmacokinetic interaction shortens oxiracetam's half-life; do not self-adjust anticonvulsant regimens.
- Caution in the elderly due to reduced clearance and accumulation.
- This is an unapproved, unregulated product in the US and many jurisdictions with no assured purity - a practical contraindication for anyone unwilling to accept unknown product quality.
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Understand the evidence honestly: there is no reliable human proof that oxiracetam enhances cognition in healthy people; the disease-population data are small, dated, and mixed, including a clearly negative Alzheimer's trial. Do not assume benefit.
- Because it is an unregulated, non-FDA/EMA-approved product, identity and purity are not guaranteed - a major uncontrolled risk. Third-party lab testing (certificate of analysis) is the minimum sanity check.
- Do not use if you have significant kidney impairment, are pregnant or breastfeeding, or have a hypersensitivity to racetams.
- If you have epilepsy or take carbamazepine/valproate (or other anticonvulsants), do not start oxiracetam or change your anticonvulsant dose on your own - there is a documented pharmacokinetic interaction; involve your neurologist.
- Get baseline and periodic bloodwork with a clinician, focusing on renal function, and share exactly what you are taking rather than concealing it.
- Stop and seek medical care for allergic reactions, seizures, severe insomnia/agitation, chest pain, palpitations, fainting, or signs of reduced kidney function.
- Avoid combining with other stimulants or unproven nootropic stacks; interactions and additive effects are unstudied, and stacking multiplies the unknowns.
- This monograph is harm-reduction information, not medical advice or an endorsement of use; decisions about any cognitive or hormonal concern should be made with a qualified clinician.
Citations (19)
Every clinical claim above is tied to a primary source. Overall evidence grade C — graded to the best available evidence for its core claims.
- 01
Oxiracetam is renally eliminated, with >90% of an intravenous dose recovered unchanged in urine, oral bioavailability ~75%, peak levels at 1-2 h, and mean residence times of ~4-6.5 h in healthy volunteers.
CohortPMID 6519128 ↗
- 02
Half-life is prolonged in the elderly (mean ~12.3 h vs ~7.7 h in younger healthy adults) due to reduced renal clearance, with roughly a doubling of AUC.
CohortPMID 2253653 ↗
- 03
In elderly patients, ~84% of an oral dose is recovered unchanged in urine within 24 h, half-life ~3-6 h, with no serum accumulation on twice-daily dosing over 7 days.
CohortPMID 3691580 ↗
- 04
Oxiracetam crosses the blood-brain barrier and persists longer in the CNS than in serum; nootropic PK data are limited.
ReviewPMID 7586900 ↗
- 05
In healthy volunteers, (S)-oxiracetam up to 2000 mg was safe and tolerated with adverse events that were mild-to-moderate and dose-independent; ~55% urine and ~36% feces excreted unchanged; half-life ~6.1-6.6 h; steady state by day 5 with mild accumulation.
- 06
Concomitant carbamazepine or valproate shortens oxiracetam's half-life (potentially requiring more frequent dosing), while oxiracetam does not alter anticonvulsant serum levels.
CohortPMID 2108837 ↗
- 07
Preclinical radioligand studies show oxiracetam binds saturable sites concentrated in the septum, hippocampus, and cerebral cortex.
PreclinicalPMID 1974611 ↗
- 08
In 12 healthy volunteers, acute oral oxiracetam dose-dependently reduced scopolamine-induced impairment of memory and attention, significant at 1600 mg on delayed word recall.
- 09
In mild-to-moderate Alzheimer's and multi-infarct dementia, oxiracetam 800 mg b.i.d. (1600 mg/day) improved several cognitive/behavioral measures versus placebo over 90 days, and safety was maintained up to 1 year with no severe adverse events and no routine-lab changes.
- 10
In mild-to-moderate dementia, oxiracetam 1600 mg/day improved attention and other neuropsychological functions versus placebo over 90 days with no side effects observed.
- 11
In degenerative dementia, oxiracetam 1600 mg/day improved cognitive function and reaction time versus placebo over 26 weeks/12 months with good tolerability.
- 12
In organic brain syndrome, oxiracetam 1600 mg/day improved cognitive function, logical performance, and attention versus placebo over 8 weeks.
- 13
In probable Alzheimer's disease, oxiracetam produced NO improvement on a broad neuropsychological battery versus placebo, indicating it was ineffective for that indication.
- 14
In multi-infarct and primary degenerative dementia, oxiracetam improved word fluency but showed mixed results including a decline on an activities-of-daily-living scale in one subgroup.
- 15
In organic brain syndrome of late life, oxiracetam (2400 mg/day) showed a trend toward global improvement with good tolerability; between-group differences did not reach statistical significance, and hematology, blood chemistry, urinalysis, and EEG were assessed.
- 16
A multiple-treatments meta-analysis grouped oxiracetam among symptomatic vascular-dementia treatments with a modest pooled cognitive benefit.
Meta-analysisPMID 29502274 ↗
- 17
A large multicenter phase IV RCT investigating oxiracetam 800 mg b.i.d. for post-stroke vascular cognitive impairment characterized the anticipated effect as at most modest.
- 18
A small RCT reported that nicergoline combined with oxiracetam improved MoCA scores more than nicergoline alone in post-stroke vascular cognitive impairment.
- 19
Efficacy and safety of oxiracetam and l-oxiracetam for memory/cognition in mild-to-moderate traumatic brain injury remain unproven and were the subject of an ongoing randomized controlled trial.
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice